Literature DB >> 18838314

Validated high performance liquid chromatography-UV detection method for the determination of daptomycin in human plasma.

Jens Martens-Lobenhoffer1, Jan T Kielstein, Catrin Oye, Stefanie M Bode-Böger.   

Abstract

Daptomycin is the first approved member of the new class cyclic lipopeptide antibiotic drugs, effective against a broad spectrum of Gram-positive bacteria. Here we present an HPLC method with UV detection capable to obtain pharmacokinetic data of daptomycin in human plasma, exemplarily shown in a critically ill patient with acute renal failure undergoing extended daily dialysis. Sample preparation consists only of protein precipitation with methanol. Chromatographic separation was achieved on a Zorbax Eclipse XDB-C8 column and daptomycin was detected at 224 nm. The calibration function was linear over the range from 3.5 to 350 microg/ml. The relative standard deviations were <2% in the intra-day and <6% in the inter-day measurements. The accuracy was always better than 7%. Daptomycin was stable in aqueous solutions for 2 months frozen at-20 degrees C. However, in plasma frozen at -20 degrees C a loss of 25% in 1 month was observed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18838314     DOI: 10.1016/j.jchromb.2008.09.019

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  7 in total

1.  Fosfomycin Enhances the Activity of Daptomycin against Vancomycin-Resistant Enterococci in an In Vitro Pharmacokinetic-Pharmacodynamic Model.

Authors:  Ashley D Hall Snyder; Brian J Werth; Poochit Nonejuie; John P McRoberts; Joe Pogliano; George Sakoulas; Juwon Yim; Nivedita Singh; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

2.  The combination of ceftaroline plus daptomycin allows for therapeutic de-escalation and daptomycin sparing against MRSA.

Authors:  Katie E Barber; Brian J Werth; Michael J Rybak
Journal:  J Antimicrob Chemother       Date:  2014-09-22       Impact factor: 5.790

3.  Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.

Authors:  Stefanie Henken; Jennifer Bohling; Jens Martens-Lobenhoffer; James C Paton; A David Ogunniyi; David E Briles; Vyvyan C Salisbury; Dirk Wedekind; Stefanie M Bode-Böger; Thomas Welsh; Franz C Bange; Tobias Welte; Ulrich A Maus
Journal:  Antimicrob Agents Chemother       Date:  2009-11-16       Impact factor: 5.191

4.  Rapid Turbidimetric Assay to Determine the Potency of Daptomycin in Lyophilized Powder.

Authors:  Eliane Gandolpho Tótoli; Hérida Regina Nunes Salgado
Journal:  Pharmaceutics       Date:  2015-07-09       Impact factor: 6.321

5.  Activity of daptomycin- and vancomycin-loaded poly-epsilon-caprolactone microparticles against mature staphylococcal biofilms.

Authors:  Inês Santos Ferreira; Ana F Bettencourt; Lídia M D Gonçalves; Stefanie Kasper; Bertrand Bétrisey; Judith Kikhney; Annette Moter; Andrej Trampuz; António J Almeida
Journal:  Int J Nanomedicine       Date:  2015-07-07

6.  Evaluation of High-Dose Daptomycin Versus Vancomycin Alone or Combined with Clarithromycin or Rifampin Against Staphylococcus aureus and S. epidermidis in a Novel In Vitro PK/PD Model of Bacterial Biofilm.

Authors:  Ashley D Hall Snyder; Celine Vidaillac; Warren Rose; John P McRoberts; Michael J Rybak
Journal:  Infect Dis Ther       Date:  2014-12-18

7.  Implementation and Comparison of Two Pharmacometric Tools for Model-Based Therapeutic Drug Monitoring and Precision Dosing of Daptomycin.

Authors:  Justine Heitzmann; Yann Thoma; Romain Bricca; Marie-Claude Gagnieu; Vincent Leclerc; Sandrine Roux; Anne Conrad; Tristan Ferry; Sylvain Goutelle
Journal:  Pharmaceutics       Date:  2022-01-04       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.